Inotiv, Inc.

  • Market Cap: Micro Cap
  • Industry: Miscellaneous
  • ISIN: US45783Q1004
USD
0.88
0.01 (1.07%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

598.91 k

Shareholding (Mar 2025)

FII

2.89%

Held by 27 FIIs

DII

84.6%

Held by 14 DIIs

Promoter

0.06%

How big is Inotiv, Inc.?

22-Jun-2025

As of Jun 18, Inotiv, Inc. has a market capitalization of 70.42 million, with net sales of 480.41 million and a net profit of -87.48 million over the latest four quarters. The company reported shareholder's funds of 170.50 million and total assets of 841.43 million as of Sep 24.

Market Cap: As of Jun 18, Inotiv, Inc. has a market capitalization of 70.42 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Inotiv, Inc. reported net sales of 480.41 million and a net profit of -87.48 million.<BR><BR>Balance Sheet Snapshot: As of Sep 24, the company reported shareholder's funds of 170.50 million and total assets of 841.43 million.

Read More

What does Inotiv, Inc. do?

22-Jun-2025

Inotiv, Inc. is an international contract research company specializing in drug discovery and development services, with a market capitalization of $70.42 million. As of March 2025, it reported net sales of $124 million and a net loss of $15 million.

Overview:<BR>Inotiv, Inc. is an international contract research company providing drug discovery and development services and analytical instruments, operating in the Miscellaneous industry with a micro-cap market capitalization.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 124 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -15 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 70.42 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 2.47 <BR>Return on Equity: -57.12% <BR>Price to Book: 0.45<BR><BR>Contact Details:<BR>Address: 2701 Kent Ave, WEST LAFAYETTE IN: 47906-1350 <BR>Tel: 1 317 4634527 <BR>Fax: 1 765 4971102 <BR>Website: http://www.basinc.com/

Read More

Should I buy, sell or hold Inotiv, Inc.?

22-Jun-2025

Who are in the management team of Inotiv, Inc.?

22-Jun-2025

As of March 2022, the management team of Inotiv, Inc. includes Dr. Gregory Davis (Interim Chairman), Mr. Robert Leasure (President and CEO), Dr. John Sagartz (Chief Strategy Officer), and three Independent Directors: Dr. Richard Johnson, Mr. R. Matthew Neff, and Ms. Wendy Perrow. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Inotiv, Inc. includes the following individuals:<BR><BR>- Dr. Gregory Davis, who serves as the Interim Chairman of the Board.<BR>- Mr. Robert Leasure, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. John Sagartz, who holds the position of Chief Strategy Officer and is also a Director.<BR>- Dr. Richard Johnson, who is an Independent Director.<BR>- Mr. R. Matthew Neff, who is another Independent Director.<BR>- Ms. Wendy Perrow, who is also an Independent Director. <BR><BR>This team is responsible for guiding the strategic direction and operations of the company.

Read More

Is Inotiv, Inc. overvalued or undervalued?

20-Sep-2025

As of February 10, 2022, Inotiv, Inc. is considered risky and overvalued with poor financial metrics and significant underperformance, reflected in a year-to-date return of -64.98% and a 3-year return of -93.17%, compared to the S&P 500's gains.

As of 10 February 2022, the valuation grade for Inotiv, Inc. has moved from fair to risky, indicating a deterioration in its financial standing. The company is currently overvalued, as evidenced by its Price to Book Value of 0.59, an EV to Sales ratio of 1.00, and a troubling ROE of -57.12%. In comparison, FONAR Corp., which is rated fair, has a P/E ratio of 8.9956 and an EV to EBITDA of 2.7084, highlighting the significant disparity in valuation metrics among peers.<BR><BR>Inotiv's performance has been notably poor, with a year-to-date return of -64.98% compared to the S&P 500's gain of 12.22%, and a staggering 3-year return of -93.17% against the S&P 500's 70.41%. This stark contrast reinforces the notion that Inotiv is not only struggling in terms of valuation but also underperforming significantly relative to broader market benchmarks.

Read More

Is Inotiv, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Inotiv, Inc. is in a bearish trend, indicated by negative MACD, moving averages, and Bollinger Bands, with a year-to-date return of -64.98% compared to the S&P 500's 12.22%.

As of 8 September 2025, the technical trend for Inotiv, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish, with key indicators supporting this view including a bearish MACD on the weekly timeframe, bearish moving averages on the daily timeframe, and a bearish signal from Bollinger Bands on both weekly and monthly timeframes. Additionally, the Dow Theory indicates a mildly bearish stance on the weekly and monthly levels. <BR><BR>In terms of performance, Inotiv has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -64.98% versus the S&P 500's 12.22%, and a 3-year return of -93.17% compared to the S&P 500's 70.41%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Low ability to service debt as the company has a high Debt to EBITDA ratio of 20.53 times

  • Low ability to service debt as the company has a high Debt to EBITDA ratio of 20.53 times
  • The company has reported losses. Due to this company has reported negative ROE
2

Flat results in Jun 25

3

Risky - Negative Operating Profits

4

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Miscellaneous

stock-summary
Market cap

USD 55 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

2.78

stock-summary
Return on Equity

-58.49%

stock-summary
Price to Book

0.38

Revenue and Profits:
Net Sales:
131 Million
(Quarterly Results - Jun 2025)
Net Profit:
-18 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-44.37%
0%
-44.37%
6 Months
-70.31%
0%
-70.31%
1 Year
-79.02%
0%
-79.02%
2 Years
-69.9%
0%
-69.9%
3 Years
-85.38%
0%
-85.38%
4 Years
-97.95%
0%
-97.95%
5 Years
-87.55%
0%
-87.55%

Inotiv, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
53.40%
EBIT Growth (5y)
-308.25%
EBIT to Interest (avg)
-0.68
Debt to EBITDA (avg)
20.53
Net Debt to Equity (avg)
2.47
Sales to Capital Employed (avg)
0.88
Tax Ratio
14.89%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
38.37%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.59
EV to EBIT
-9.21
EV to EBITDA
73.62
EV to Capital Employed
0.88
EV to Sales
1.00
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-9.57%
ROE (Latest)
-57.12%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 18 Schemes (12.46%)

Foreign Institutions

Held by 27 Foreign Institutions (2.89%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 5.15% vs 3.67% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -18.12% vs 46.01% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "130.70",
          "val2": "124.30",
          "chgp": "5.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "9.00",
          "val2": "4.90",
          "chgp": "83.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "13.60",
          "val2": "13.40",
          "chgp": "1.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "6.50",
          "chgp": "-101.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.60",
          "val2": "-14.90",
          "chgp": "-18.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-37.80%",
          "val2": "-71.80%",
          "chgp": "3.40%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Sep 2024 is -14.27% vs 4.51% in Sep 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Sep 2024 is -3.81% vs 68.90% in Sep 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "490.70",
          "val2": "572.40",
          "chgp": "-14.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "7.30",
          "val2": "52.30",
          "chgp": "-86.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "46.90",
          "val2": "43.00",
          "chgp": "9.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-33.30",
          "val2": "-72.20",
          "chgp": "53.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-108.90",
          "val2": "-104.90",
          "chgp": "-3.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-101.40%",
          "val2": "-4.20%",
          "chgp": "-9.72%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
130.70
124.30
5.15%
Operating Profit (PBDIT) excl Other Income
9.00
4.90
83.67%
Interest
13.60
13.40
1.49%
Exceptional Items
-0.10
6.50
-101.54%
Consolidate Net Profit
-17.60
-14.90
-18.12%
Operating Profit Margin (Excl OI)
-37.80%
-71.80%
3.40%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 5.15% vs 3.67% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -18.12% vs 46.01% in Mar 2025

Annual Results Snapshot (Consolidated) - Sep'24stock-summary
Sep'24
Sep'23
Change(%)
Net Sales
490.70
572.40
-14.27%
Operating Profit (PBDIT) excl Other Income
7.30
52.30
-86.04%
Interest
46.90
43.00
9.07%
Exceptional Items
-33.30
-72.20
53.88%
Consolidate Net Profit
-108.90
-104.90
-3.81%
Operating Profit Margin (Excl OI)
-101.40%
-4.20%
-9.72%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Sep 2024 is -14.27% vs 4.51% in Sep 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Sep 2024 is -3.81% vs 68.90% in Sep 2023

stock-summaryCompany CV
About Inotiv, Inc. stock-summary
stock-summary
Inotiv, Inc.
Miscellaneous
Bioanalytical systems, Inc. is an international contract research company providing drug discovery and development services and analytical instruments. The Company operates in two segments: contract research services and research products. The contract research services segment provides research and development support on a contract basis to pharmaceutical companies. The research products segment provides liquid chromatography, electrochemical and physiological monitoring products to pharmaceutical companies, universities, government research centers, and medical research institutions. The Company supports the preclinical and clinical development needs of researchers and clinicians for small molecule and large biomolecule drug candidates. The contract research services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance and quality control testing.
Company Coordinates stock-summary
Company Details
2701 Kent Ave , WEST LAFAYETTE IN : 47906-1350
stock-summary
Tel: 1 317 4634527
stock-summary
Registrar Details